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ABSTRACT
Objective To compare all-cause and liver-related
hospital resource use in the 6 and 12 months
pre-rifaximin-α and post-rifaximin-α initiation in
UK patients with hepatic encephalopathy (HE).
Design A UK multicentre, retrospective,
observational study. Patients’ medical records
were reviewed for demographics, clinical
outcomes and adverse events (AEs) to rifaximin-α.
Details of hospital admissions/attendances in the
6 and 12 months pre-rifaximin-α and post-
rifaximin-α initiation were extracted from hospital
electronic databases.
Setting 13 National Health Service centres.
Patients 207 patients with HE who initiated
rifaximin-α between July 2008 and May 2014.
Hospital resource use data were available for
145/207 patients.
Main outcome measure Change in mean
number of liver-related hospital bed days/patient
(total and critical care) between the 6 months
pre-rifaximin-α and post-rifaximin-α initiation.
Results Comparing the 6 months pre-rifaximin-α
and post-rifaximin-α initiation in alive patients at
the end of the observation period (N=114): there
were significant reductions in the mean number
of hospitalisations/patient (liver-related 1.3 to
0.5, p<0.001; all-cause 1.9 to 0.9, p<0.001),
hospital bed days/patient (liver-related 17.8 to
6.8, p<0.001; all-cause 25.4 to 10.6, p<0.001),
30-day hospital readmissions/patient (liver-related
0.5 to 0.2, p=0.039; all-cause 0.8 to 0.4,
p=0.024) and emergency department (ED)
attendances/patient (all-cause, 1.0 to 0.5,
p<0.001). The mean critical care bed days/
patient reduced significantly for all-cause
admissions (1.3 to 0.3, p=0.049); non-significant
reduction for liver-related admissions. 4% of
patients (9/207) developed AEs.
Conclusions In UK clinical practice, treatment
with rifaximin-α for HE is well-tolerated and
associated with significant reductions in
hospitalisations, bed days (including critical care),
ED attendances and 30-day readmissions.
INTRODUCTION
Hepatic encephalopathy (HE) is a well-
recognised complication of cirrhosis,
which is associated with considerable
morbidity and mortality. Subtle signs of
HE are observed in approximately 60%1
and overt HE (OHE) in about 30–45%
of patients with cirrhosis.2 After a first
OHE episode, the 1-year cumulative
probability of recurrence is 40%,3 and
the 1-year and 3-year survival probabil-
ities are 42% and 23%, respectively.4 The
mortality risk associated with HE is
higher than that associated with other
major hepatic decompensation events.5
HE can adversely affect patients’ quality
of life (QoL) and cognitive function.6 7
  243Hudson M, et al. Frontline Gastroenterology 2017;8:243–251. doi:10.1136/flgastro-2016-100792
Liver
To cite: Hudson M, 
Radwan A, Di Maggio P, et al. 
Frontline Gastroenterology 
2017;8:243–251.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
flgastro- 2016- 100792).
For numbered affiliations see end 
of article.
Correspondence to
Dr Paola Di Maggio, UK Medical 
Affairs, Norgine, Moorhall Road, 
Harefield, Uxbridge, London UB9 
6NS, UK;  
 pdimaggio@ norgine. com
Received 9 December 2016
Revised 6 March 2017
Accepted 17 March 2017
Published Online First 
7 April 2017
 ► http:// dx. doi. org/ 10. 1136/ 
flgastro- 2017- 100852
group.bmj.com on November 13, 2017 - Published by http://fg.bmj.com/Downloaded from 
Furthermore, because OHE requires hospital manage-
ment, it places a considerable burden on healthcare
resources.8
Treatment for HE aims to resolve OHE episodes
and prevent recurrences.9 Rifaximin-α (TARGAXAN,
Norgine) is a minimally absorbed, oral antibiotic
which has been shown, in clinical trials, to reduce the
risk of OHE episodes, HE-related hospitalisations and
improve health-related QoL, compared with
placebo.10–12 It is licensed for the reduction in recur-
rence of OHE episodes and, in March 2015, the
National Institute for Health and Care Excellence
(NICE) approved Technology Appraisal 337 (TA337)
for rifaximin-α use in the UK National Health Service
(NHS) within its marketing authorisation.13
Currently, there is limited information describing
the impact of rifaximin-α on healthcare resource use
in a real-world setting. This is critical to enable clin-
ical decision makers to evaluate the cost-effectiveness
of rifaximin-α in routine clinical practice. A number
of UK audits have shown reductions in all-cause hos-
pitalisations and bed occupancy with rifaximin-α
treatment,14–18 but these were mainly single-centre
studies and the results need to be confirmed in a
range of centres using a standardised data collection
methodology. To date, no European studies have been
published on the impact of rifaximin-α on critical care
admissions, emergency department (ED) attendances
and 30-day emergency readmissions.
IMPRESS was a retrospective, observational study
conducted in 13 UK centres ranging from District
General Hospitals to liver transplant units to evaluate
the real-world impact of rifaximin-α on all-cause and
liver-related NHS hospital resource use.
MATERIALS AND METHODS
Patient population and data collection
The study was conducted between August 2014 and
June 2015 in 13 geographically dispersed UK NHS
hospitals.
Patients with a documented clinical diagnosis of
HE, who were initiated on rifaximin-α ≥12 months
before data collection, were included in the study.
Exclusion criteria included initiation of rifaximin-α at
other hospitals or in primary care and unavailability
of medical records. Patients with new prescriptions
for rifaximin-α were identified from pharmacy
records and selected in reverse chronological order
until the centre-specific recruitment target was
reached (or until all eligible patients were identified, if
below target).
Patients’ medical records were reviewed for baseline
demographic and disease characteristics, rifaximin-α
prescribing, concomitant medications, clinical out-
comes and adverse events (AEs) during treatment.
Resource use data were extracted from hospitals’
central management information systems; parameters
included hospitalisations, critical care admissions,
non-elective admissions, 30-day emergency readmis-
sions, ED attendances and reasons for hospitalisations
(using International Classification of Diseases
(ICD)-10 codes). The maximum observation period
for each patient was 12 months before and after the
date of rifaximin-α initiation, irrespective of treatment
duration.
A ‘liver-related’ hospitalisation was defined as any
hospitalisation with a primary ICD-10 diagnosis code
of K70-77/C22.0/I85-86 (see online supplementary
table S1). For hospitalisations with the primary
ICD-10 codes R18/R41.0/R41/G93.4/F10.3/F05.9/
I98.2/I98.3 (see online supplementary table S2), ano-
nymised records were reviewed on a case-by-case basis
by a medical representative of the study sponsor to
determine whether the admission was liver-related.
Primary and secondary outcomes
The primary outcome was the change in the mean
number of liver-related hospital bed days per patient
(total and critical care) between the 6 months
pre-rifaximin-α and post-rifaximin-α initiation.
Secondary outcomes included changes between the 6
or 12 months pre-rifaximin-α and post-rifaximin-α
initiation in the number of all-cause and liver-related
hospitalisations (overnight stay), hospital bed days,
critical care admissions and bed days, non-elective
admissions, 30-day emergency readmissions (defined
as a hospital admission occurring within 30 days of a
previous discharge) and ED attendances (without
admission); also clinical outcomes and AEs.
Statistical analysis
The target sample size of 250–300 patients was based
on two previous UK evaluations,15 17 in which reduc-
tions of ∼1.5 hospital bed days/patient/month were
observed in the 6 months post-rifaximin-α initiation.
To describe a similar reduction at p<0.05, a sample
of 25–30 patients was required. It was important for
the sample size to give sufficient reliability for analysis
of both the overall study population and subgroups of
patients with different Model for End-Stage Liver
Disease (MELD) scores. A MELD score of 19–24 was
expected to occur at a frequency of ∼10%;10 a 10%
subgroup of 25–30 thus required an overall sample of
250–300. Analyses were conducted using Microsoft
Excel and Stata using the available data, with no
imputation of missing values.
Resource use endpoints were analysed for the
intention-to-treat (ITT) population and for the patients
who were alive (‘surviving patients’) at the end of the
period investigated (6 or 12 months post-rifaximin-α
initiation). The latter analysis was conducted to reduce
non-survivor confounding, as resource use, calculated
including deceased patients, may overestimate the
benefit of rifaximin-α. The statistical significance of
the mean change for each parameter was calculated
using a paired t-test.
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RESULTS
Patient and treatment characteristics
The study included 207 patients (range 5–25 per
centre), who initiated rifaximin-α between 3 July
2008 and 8 May 2014. Resource use data were avail-
able for 145 patients (70%), from 11 of the 13
centres. The flow of patients through the study is
shown in figure 1. Table 1 summarises patient baseline
characteristics, which did not differ significantly
between the total sample and the resource use cohort.
The mean age of patients was 59 years (SD±11.4) at
diagnosis of HE, 61% were male and 64% had
alcohol-related liver disease (ARLD) (table 1).
Rifaximin-α and lactulose treatment are presented
in table 1. Rifaximin-α was discontinued within
12 months in 43% (88/207) of patients, most com-
monly due to death (52%, 46/88), transplant (14%,
12/88) or HE resolution (7%, 6/88). Of the 88
patients who discontinued treatment, 47% (41/88)
stopped <12 weeks, 22% (19/88) 12<26 weeks and
28% (25/88) 26<52 weeks after rifaximin-α initiation
(3% (3/88), time unknown).
Clinical outcomes
A total of 81% (168/207) of patients were alive at
6 months and 73% (152/207) at 12 months
post-rifaximin-α initiation. There were 55 deaths; of
these, 55% (30/55) were known to be related to
ARLD or end-stage liver disease, although no specific
cause of death was documented. Causes of death in
the remaining patients included hepatocellular carcin-
oma (11%, 6/55), pneumonia (7%, 4/55), multiorgan
failure (5%, 3/55), gastrointestinal bleed (5%, 3/55)
and other (5%, 3/55); cause not documented in 11%
(6/55) of patients. The mean baseline MELD score
was 15.8 (SD±8.1) in surviving and 20.7 (SD±6.4) in
deceased patients.
Overall, OHE episodes were experienced by
57% (117/207) of patients in the 12 months pre-
rifaximin-α versus 38% (79/207) in the 12 months
post-rifaximin-α initiation; the mean number of
episodes per patient (N=207) decreased from 1.01
(SD±1.5) in the 12 months pre-rifaximin-α to 0.77
(SD±1.3) in the 12 months post-rifaximin-α initi-
ation (p=0.047). In the subgroup of 152 patients
who were alive at 12 months post-rifaximin-α initi-
ation, OHE episodes were experienced by 55% (84/
152) of patients in the 12 months pre-rifaximin-α
versus 36% (55/152) in the 12 months post-
rifaximin-α initiation; the mean number of
episodes per patient (N=152) decreased from 1.02
(SD±1.3) in the 12 months pre-rifaximin-α to 0.74
(SD±1.3) in the 12 months post-rifaximin-α ini-
tiation (p=0.068).
During the study, 6% (13/207) of patients received
a liver transplant and 9% (16/173 with data available)
were placed on a palliative care pathway. At
12 months post-rifaximin-α initiation, 9% (11/118) of
the patients who were alive and on rifaximin-α were
not abstinent.
Safety data
Nine patients (4%) had documented AEs: Clostridium
difficile infection (n=4), rash (n=2), abdominal pain,
vomiting and discolouration of teeth (one patient
each). No serious AEs were reported. Of the four
patients who developed C difficile infection, none had
a history of C difficile and none was on concomitant
antibiotics. All patients continued rifaximin-α therapy.
Resource use: ITT population
The number of liver-related hospital bed days
(primary outcome), critical care bed days and hospita-
lisations per patient in the pre-rifaximin-α and
post-rifaximin-α initiation periods is shown in figure 2
for the ITT population; this analysis included
deceased patients.
In the 6 months post-rifaximin-α initiation, there
were reductions in the mean number of liver-related
hospitalisations (p<0.001), hospital bed days
(p<0.001) and critical care bed days (p=0.068) per
patient (figure 2). Similar results were observed for
the 12-month rifaximin-α period, however, with a sig-
nificant reduction in critical care bed days per patient
(p=0.035) (figure 2).
Resource use: surviving patients
The analysis in ‘surviving patients’ included 114
patients alive at 6 months and 102 patients alive at
12 months post-rifaximin-α initiation.
The proportion of hospitalised patients decreased
from 69% (79/114) in the 6 months pre-rifaximin-α
to 32% (37/114) in the 6 months post-rifaximin-α ini-
tiation for liver-related hospitalisations and from 80%
(91/114) to 50% (57/114) for all-cause hospitalisa-
tions. For the 12 months pre-rifaximin-α and
post-rifaximin-α initiation, the proportion of hospita-
lised patients decreased from 72% (73/102) to 44%
(45/102) for liver-related hospitalisations and from
85% (87/102) to 65% (66/102) for all-cause; 3% (3/
102) of patients had no hospitalisations. Overall, 63%
(170/271) of all hospitalisations in the 12 months
pre-rifaximin-α and 49% (83/168) in the 12 months
post-rifaximin-α initiation were liver-related.
Hospital resource use in surviving patients is shown
in table 2. In the 6 months post-rifaximin-α initiation,
there were significant reductions in the mean number
of hospitalisations per patient (p<0.001 liver-related,
p<0.001 all-cause), hospital bed days per patient
(p<0.001 liver-related, p<0.001 all-cause) and hos-
pital bed days per admission (p=0.001 liver-related,
p=0.001 all-cause). Similar reductions were observed
for the 12-month observation period.
There were also significant reductions in liver-
related and all-cause critical care admissions per
patient at both 6 (p=0.027 liver-related, p=0.008
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all-cause) and 12 months (p=0.01 liver-related,
p=0.002 all-cause) post-rifaximin-α initiation. The
reduction in all-cause critical care bed days per patient
was significant at both 6 (p=0.049) and 12 months
(p=0.021), but the reduction in liver-related critical
care bed days was not significant at either time point
(table 2, see online supplementary figure S1).
There were significant reductions in liver-related
and all-cause non-elective admissions at both 6
(p<0.001 liver-related, p<0.001 all-cause) and
12 months (p<0.001 liver-related, p=0.006 all-
cause).
There were significant reductions in both liver-
related and all-cause 30-day emergency readmissions
at 6 months (p=0.039 liver-related, p=0.024 all-
cause); however, the reductions at 12 months were
not significant. Similarly, for ED attendances (all-cause
only) there was a significant reduction at 6 (p<0.001)
but not 12 months (table 2).
In the subgroup of alive patients prescribed
rifaximin-α 1100 mg/day (n=31, 6 months; n=30,
12 months), significant reductions in all-cause hospita-
lisations and bed days per patient were observed at
6 months, and were maintained at 12 months (see
online supplementary table S3).
All-cause and liver-related resource use calculated
in surviving patients with ≥1 admissions/attendances in
the observed periods is shown in online supplementary
table S4.
DISCUSSION
IMPRESS included 207 UK patients with HE treated
with rifaximin-α in routine clinical practice. Treatment
with rifaximin-α was well-tolerated and associated
with significant reductions in all-cause hospitalisations
and bed days, affirming the findings of previous ran-
domised controlled trials (RCTs) and UK audits.14–18
Also, importantly, there were significant reductions in
Figure 1 Study flow. RFX, rifaximin-α.
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Table 1 Baseline demographic, disease and treatment characteristics
Characteristic Total sample (N=207) Resource use cohort (N=145)
Gender (n, %)
Male 127 (61%) 89 (61%)
Female 80 (39%) 56 (39%)
Age (years) — mean (±SD)
At diagnosis of cirrhosis 57.3 (±11.9) N=191 58.7 (±11.7) N=132
At diagnosis of HE 59.3 (±11.4) 60.3 (±11.5)
At initiation of rifaximin-α 60.0 (±11.4) 60.9 (±11.5)
Baseline Child-Pugh score (n, %)
A 12 (6%) 7 (5%)
B 58 (28%) 36 (25%)
C 44 (21%) 24 (17%)
Not recorded 93 (45%) 78 (54%)
Baseline MELD score (n, %)
≤10 29 (14%) 19 (13%)
11–18 76 (37%) 43 (30%)
19–24 25 (12%) 14 (10%)
≥25 29 (14%) 19 (13%)
Not recorded 48 (23%) 50 (34%)
Time from cirrhosis diagnosis to initiation of rifaximin-α, months
Mean (SD) 38.8 (49.2) N=191 33.9 (±46.6) N=132
Median (IQR) 22.4 (6.8–54.3) 17.9 (4.7–47.3)
Time from HE diagnosis to initiation of rifaximin-α, months
Mean (SD) 8.3 (17.5) 7.5 (±15.1)
Median (IQR) 1.6 (0.1–9.0) 1.9 (0.1–9.2)
Underlying liver disease aetiology (not mutually exclusive)
Alcohol-related liver disease 133 (64%) 98 (68%)
Non-alcoholic steatohepatitis 50 (24%) 32 (22%)
Hepatitis B or C 22 (11%) 13 (9%)
Autoimmune hepatitis 5 (2%) 2 (1%)
Primary biliary cirrhosis 1 (0.5%) 0 (0%)
Haematochromatosis 1 (0.5%) 0 (0%)
Non-alcoholic fatty liver disease 2 (1%) 2 (1%)
Cryptogenic 6 (3%) 5 (3%)
Other 7 (3%) 6 (4%)
Not recorded 2 (1%) 2 (1%)
Rifaximin-α dose (n, %)
1100 mg/day 70 (34%) 43 (30%)
1200 mg/day 126 (61%) 93 (64%)
Other doses 11 (5%) 9 (6%)
Rifaximin-α initiated during an overt HE episode 152 (73%) 100 (69%)
Patients drinking alcohol at rifaximin-α initiation (n, %)
Yes 35 (17%) 26 (18%)
No 143 (69%) 102 (70%)
Unknown 29 (14%) 17 (12%)
Concomitant lactulose use (n, %) 174 (84%) 119 (82%)
Listed for liver transplantation (n, %) 19 (9%) 7 (5%)
There were no significant differences between the total sample and the resource use cohort in gender distribution (χ2 test, p=0.996), age (t-test,
p=0.2961 (at diagnosis of cirrhosis), p=0.402 (at diagnosis of HE), p=0.4681 (at initiation of rifaximin-α)) or baseline MELD score (χ2 test, p=0.221).
Remaining characteristics not compared.
HE, hepatic encephalopathy; MELD, Model for End-Stage Liver Disease.
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critical care admissions and bed days, non-elective
admissions, 30-day emergency readmissions and ED
attendances, which have not been demonstrated previ-
ously. Statistically significant reductions in liver-related
resource use were observed within 6 months of treat-
ment initiation and largely sustained at 12 months.
Clinical outcomes
The proportion of patients experiencing OHE epi-
sodes decreased in the 12 months post-rifaximin-α ini-
tiation (absolute reduction 18% in the overall group)
and the number of episodes per patient also decreased
significantly. Although anticipated, this finding
Figure 2 Liver-related resource use in the 6 and 12 months pre-rifaximin-α and post-rifaximin-α initiation — intention-to-treat
population.
Table 2 Resource use in surviving patients
6 months (N=114) 12 months (N=102)
Resource use parameter* n†
Pre-RFX
initiation‡
Post-RFX
initiation‡
p
Value§ n†
Pre-RFX
initiation‡
Post-RFX
initiation‡
p
Value§
Liver-related resource use
Total hospital bed days 89 2034 769 – 85 2135 910 –
Hospitalisations per patient 89 1.3 (0.1) 0.5 (0.1) <0.001 85 1.7 (0.2) 0.8 (0.1) <0.001
Hospital bed days per patient 89 17.8 (2.6) 6.8 (1.5) <0.001 85 20.9 (2.9) 8.9 (1.9) <0.001
Hospital bed days per admission 89 10.9 (1.5) 4.8 (1.1) 0.001 85 10.9 (1.4) 5.2 (1.2) 0.002
Critical care admissions per patient 16 0.2 (0.04) 0.1 (0.02) 0.027 15 0.2 (0.04) 0.1 (0.03) 0.01
Critical care bed days per patient 16 1.1 (0.4) 0.3 (0.2) 0.109 15 1.4 (0.5) 0.3 (0.2) 0.059
Non-elective admissions per patient 74 1.0 (0.1) 0.4 (0.1) <0.001 71 1.3 (0.2) 0.6 (0.1) <0.001
30-Day emergency readmissions per patient 37 0.5 (0.1) 0.2 (0.1) 0.039 34 0.6 (0.2) 0.3 (0.1) 0.084
All-cause resource use
Total hospital bed days 101 2890 1206 – 99 3138 1621 –
Hospitalisations per patient 101 1.9 (0.2) 0.9 (0.1) <0.001 99 2.7 (0.3) 1.7 (0.2) 0.002
Hospital bed days per patient 101 25.4 (2.9) 10.6 (2.1) <0.001 99 30.8 (3.5) 15.9 (2.9) <0.001
Hospital bed days per admission 101 12.5 (1.5) 6.4 (1.3) 0.001 99 12.6 (1.5) 5.8 (0.9) <0.001
Critical care admissions per patient 19 0.2 (0.04) 0.1 (0.02) 0.008 18 0.2 (0.05) 0.1 (0.03) 0.002
Critical care bed days per patient 19 1.3 (0.5) 0.3 (0.2) 0.049 18 2.0 (0.6) 0.4 (0.3) 0.021
Non-elective admissions per patient 88 1.6 (0.2) 0.8 (0.1) <0.001 87 2.2 (0.3) 1.3 (0.2) 0.006
30-Day emergency readmissions per patient 50 0.8 (0.2) 0.4 (0.1) 0.024 52 0.9 (0.2) 0.6 (0.1) 0.16
ED attendances per patient¶ 61 1.0 (0.2) 0.5 (0.1) <0.001 62 1.5 (0.3) 1.1 (0.2) 0.116
Definitions: ‘Hospitalisation’ includes overnight stay admissions only (ie, excluding day case); it includes both non-elective (unplanned) admissions (via ED
or GP direct referral route) and elective (planned) admissions. ‘ED attendance’ includes only attendances which did not result in hospital admission.
*Data are presented for all surviving patients at the end of 6 months (N=114) or 12 months (N=102).
†Number of patients with ≥1 admission/attendance in the observed periods (pre-RFX, post-RFX or both).
‡Shown as the mean (SEM) per patient.
§Paired t-test.
¶Data only available for all-cause (not liver-related).
ED, emergency department; GP, general practitioner; RFX, rifaximin-α.
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confirms the improvements in HE outcomes observed
in rifaximin-α clinical trials in routine clinical
practice.10
The mortality rate in this study (19% at 6 months,
27% at 12 months) is similar to the recent seven-
centre UK audit (12-month mortality 21%)18 but
higher than the pivotal trial (6-month mortality 6.4%
in rifaximin-α-treated patients).10 This difference is
likely to be because patients with MELD scores ≥25
were excluded from the RCT.10
The low number of AEs and C difficile cases in our
study demonstrates good tolerability and is consistent
with both the clinical trials of rifaximin-α and previ-
ous UK audits.10 12 18 All patients experiencing C dif-
ficile had several other risk factors; rifaximin-α
therapy was maintained.
Resource use
Overall, this study indicates a large burden of inpatient
hospital care for HE patients, with 97% of the surviving
patients hospitalised during the 24-month observation
period and 51% having at least one 30-day emergency
readmission. There are limited UK studies quantifying
the resource use burden associated with HE with which
to compare these results.18 19 However, the pattern of
repeat hospitalisations in HE patients has been widely
reported and is associated with negative consequences
including increased in-hospital mortality.6 20 In the
present study, fewer patients were hospitalised in the
post-rifaximin-α initiation period, and the number of
all-cause hospitalisations and bed days, as well as critical
care admissions and bed days, reduced significantly. The
reduction in all-cause hospital bed days per patient from
30.8 in the 12 months pre-rifaximin-α to 15.9 in the
12 months post-rifaximin-α initiation, in the ‘surviving
patient’ group, is similar to the recent seven-centre
audit.18 There were also significant reductions in all-
cause non-elective hospitalisations, ED attendances and
30-day emergency readmissions, suggesting that
rifaximin-α is associated with a considerable reduction
in the burden of unplanned hospital care for patients
with HE.
In addition to all-cause resource use, the present
study demonstrated significant reductions in liver-
related hospitalisations and bed days after rifaximin-α
initiation, not evaluated in the earlier UK audits.
As the estimated cost of a general liver-related hos-
pitalisation is £400/day21 and a critical care admission
for patients with cirrhosis £1000/day,22 these findings
suggest potential for significant NHS cost reductions
and will be useful to payers and clinical decision
makers when evaluating the cost-effectiveness of
rifaximin-α.
Strengths and limitations
IMPRESS was conducted in a real-world setting in a
range of geographically dispersed UK centres. Baseline
patient characteristics were similar to previous
studies,10 18 and broadly representative of UK patients
with advanced liver disease.23 Consequently, the data
should be generalisable to wider patient populations.
Additionally, we evaluated a broader range of resource
use descriptors than previous UK audits; the impact of
rifaximin-α on critical care resources, 30-day emer-
gency readmissions, ED attendances and liver-related
admissions specifically, has not been studied
previously.
There are a number of limitations. This was not an
RCT, rather, patients acted as their own controls in a
pre-study versus post-study design. This is a well-
established method in observational research, which
was employed in previous UK audits of rifaximin-α
effectiveness; nevertheless, the results are open to
confounding by the effects of unidentified changes in
management over time, such as referral for liver trans-
plantation, placement on the palliative care pathway,
increased contact with specialist hepatologists or
reduced alcohol consumption. However, overall, the
comparison between the pre-rifaximin-α and
post-rifaximin-α periods is probably biased against
rifaximin-α since the patients’ condition will have
deteriorated over time.
The study quantifies resource use in the hospital
setting only, not including primary care, hospices or
nursing homes, but this limitation applies equally in
both observation periods.
Although we planned to include 250 patients in the
study, resource use data were only available for ana-
lysis from 145 patients; this may have affected the
power of the study and its ability to detect differences
between the pre-rifaximin-α and post-rifaximin-α ini-
tiation periods. Nevertheless, significant changes were
observed in most resource use parameters.
The classification of liver-related and all-cause
resource use involved a degree of subjective interpret-
ation and the validity of categorisation could have
been affected by factors including clinical coding
accuracy and inconsistencies between centres.
Additionally, the involvement of the study sponsor
(rather than an independent source) in this process is
a potential source of commercial bias.
CONCLUSIONS
This study provides strong evidence for the positive
impact of rifaximin-α on NHS hospital resource use
in the real-world setting. The findings confirm the
reductions in hospitalisations and bed days observed
in previous studies and, additionally, show significant
reductions in critical care resources, non-elective
admissions, 30-day emergency readmissions and ED
attendances. Overall, the results support the use of
rifaximin-α for HE management to improve care and
outcomes for patients with advanced liver disease. A
prospective real-world study investigating the resource
use, clinical effectiveness and safety of rifaximin-α in
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HE (NCT02488993) is underway and will address
some of the limitations of this study.
Significance of this study
What is already known on this topic
A number of single-centre UK audits have shown reduc-
tions in all-cause hospitalisation frequency and bed occu-
pancy with rifaximin-α treatment, but these results need
to be confirmed in a range of centres.
What this study adds
This is the first UK study that provides clear evidence of
the positive real-world impact of rifaximin-α on National
Health Service hospital resource use. There were signifi-
cant reductions in all-cause hospitalisations and bed
days, and in critical care admissions and bed days.
Reductions were also seen in non-elective admissions,
30-day emergency readmissions and ED attendances,
which were significant within 6 months of treatment ini-
tiation and largely sustained at 12 months. In addition to
all-cause resource use, the present study demonstrated
significant reductions in liver-related hospital bed days
and hospitalisations after rifaximin-α initiation, not eva-
luated in the earlier UK audits.
How might it impact on clinical practice in the
foreseeable future
This study supports the use of rifaximin-α for the ma-
nagement of hepatic encephalopathy in patients with
advanced liver disease and will help clinical decision
makers to evaluate the cost-effectiveness of rifaximin-α
to advocate its use in routine clinical care.
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